BACKGROUND: Anti-Saccharomyces cerevisae antibody (ASCA) and perinuclear anti-neutrophil cytoplasmatic antibody (pANCA) remain the most well-established markers in inflammatory bowel disease (IBD), and both may be associated with disease phenotype. AIM: To determine the utility of ASCA and pANCA as markers in a Brazilian cohort of IBD patients. MATERIALS AND METHODS: A total of 90 patients with ulcerative colitis (UC), 77 patients with Crohn's disease (CD), and 57 healthy individuals were included in the study. ASCA was determined by enzyme-linked immunosorbent assay (ELISA) and pANCA by immunofluorescence assay. RESULTS: In support of diagnosis of UC, the sensitivity and specificity of pANCA were 51% and 100%, respectively. ASCA (IgA or IgG isotypes) presented sensitivity of 62% and specificity of 93% for CD. The combination of ASCA negativity and pANCA positivity (ASCA-/pANCA+) displayed sensitivity of 43% and specificity of 100% for diagnosis to UC. In CD patients, ASCA+/pANCA- presented sensitivity and specificity of 57% and 93%, respectively. Additionally, ASCA positivity correlated with early age at disease onset and ileal location in CD patients. In UC patients, pANCA positivity was correlated with pancolitis or left colitis. CONCLUSIONS: The results evidenced that low sensitivity of ASCA and pANCA markers limits their use in IBD screening in the general population; however, their specificity may contribute to differentiation between CD and UC in IBD patients. Our study lends further support to the suggestion that serologic assessment identifies different subtypes of IBD.
BACKGROUND: Anti-Saccharomyces cerevisae antibody (ASCA) and perinuclear anti-neutrophil cytoplasmatic antibody (pANCA) remain the most well-established markers in inflammatory bowel disease (IBD), and both may be associated with disease phenotype. AIM: To determine the utility of ASCA and pANCA as markers in a Brazilian cohort of IBD patients. MATERIALS AND METHODS: A total of 90 patients with ulcerative colitis (UC), 77 patients with Crohn's disease (CD), and 57 healthy individuals were included in the study. ASCA was determined by enzyme-linked immunosorbent assay (ELISA) and pANCA by immunofluorescence assay. RESULTS: In support of diagnosis of UC, the sensitivity and specificity of pANCA were 51% and 100%, respectively. ASCA (IgA or IgG isotypes) presented sensitivity of 62% and specificity of 93% for CD. The combination of ASCA negativity and pANCA positivity (ASCA-/pANCA+) displayed sensitivity of 43% and specificity of 100% for diagnosis to UC. In CDpatients, ASCA+/pANCA- presented sensitivity and specificity of 57% and 93%, respectively. Additionally, ASCA positivity correlated with early age at disease onset and ileal location in CDpatients. In UC patients, pANCA positivity was correlated with pancolitis or left colitis. CONCLUSIONS: The results evidenced that low sensitivity of ASCA and pANCA markers limits their use in IBD screening in the general population; however, their specificity may contribute to differentiation between CD and UC in IBD patients. Our study lends further support to the suggestion that serologic assessment identifies different subtypes of IBD.
Authors: S Vermeire; S Joossens; M Peeters; F Monsuur; G Marien; X Bossuyt; P Groenen; R Vlietinck; P Rutgeerts Journal: Gastroenterology Date: 2001-03 Impact factor: 22.682
Authors: W J Sandborn; E V Loftus; J F Colombel; K A Fleming; F Seibold; H A Homburger; B Sendid; R W Chapman; W J Tremaine; D K Kaul; J Wallace; W S Harmsen; A R Zinsmeister; S R Targan Journal: Inflamm Bowel Dis Date: 2001-08 Impact factor: 5.325
Authors: E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan Journal: Gastroenterology Date: 1996-06 Impact factor: 22.682
Authors: Frank H Klebl; Frauke Bataille; Claudia R Bertea; Hans Herfarth; Ferdinand Hofstädter; Jürgen Schölmerich; Gerhard Rogler Journal: Inflamm Bowel Dis Date: 2003-09 Impact factor: 5.325